ACPU
HZNP

Arrowgrass Capital Partners (US)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-80,000
Closed -$2.08M – 586
2015
Q1 		$2.08M Buy
+80,000
New +$1.47M 0.03% 252

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Lone Pine Capital
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s HZNP Position: Q2 2015 in Review

Arrowgrass Capital Partners (US) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2015, closing a stake of 80,000 shares — an estimated $2.08M sold.

Arrowgrass Capital Partners (US) first reported a position in HZNP in Q1 2015 and held it in 1 quarter. The position peaked at $2.08M in Q1 2015. 213 funds tracked by Wall St. Rank hold HZNP as of Q2 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 80,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2015, an estimated $2.08M.
  • Arrowgrass Capital Partners (US) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2015 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.08M in Q1 2015.
  • 213 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2015, filed 14 Aug 2015.